GT Biopharma Inc GTBP.OQ GTBP.O is expected to report resultson August 12 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for GT Biopharma Inc is for a loss of 68 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for GT Biopharma Inc is $11.00, about 83.4% above its last closing price of $1.83
This summary was machine generated August 8 at 12:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)